Key result
Perinatal stroke has a multifactorial etiology with limited treatment options; anticoagulation is rarely indicated for arterial ischemic stroke but appears safe for cerebral sinovenous thrombosis.
Why the study?
What are the epidemiology, risk factors, and treatment strategies for perinatal arterial ischemic stroke and cerebral sinovenous thrombosis?
What are the epidemiology, risk factors, and treatment strategies for perinatal arterial ischemic stroke and cerebral sinovenous thrombosis?
This review highlights that while anticoagulation is rarely indicated for perinatal arterial ischemic stroke, it appears safe and potentially effective for cerebral sinovenous thrombosis, though further clinical trials are needed.
Answers are grounded in this paper and cite their sources.
Anticoagulation may be considered for perinatal CSVT but not AIS; leaves open need for RCTs to confirm safety and efficacy.
Stroke is more likely to occur in the perinatal period than any other time in childhood, and these events can lead to a lifetime of intellectual and motor disabilities, epilepsy, and behavioral challenges. This review describes the epidemiology and natural history of perinatal arterial ischemic stroke (PAIS) and cerebral sinovenous thrombosis (CSVT), risk factors for these complications, recent evidence regarding treatment strategies, and current gaps in knowledge. Existing evidence demonstrates the multifactorial etiology of symptomatic ischemic stroke in neonates, which includes a combination of maternal, delivery, and neonatal factors. The importance of inherited thrombophilia in the pathophysiology and long-term outcomes of perinatal stroke requires additional study. At this time, there is no evidence to support routine extensive thrombophilia screening outside of a research setting. Despite the frequency of perinatal stroke and its association with substantial morbidity, treatment strategies are currently limited, and prevention strategies are nonexistent. Anticoagulation is rarely indicated in PAIS, and more work needs to focus on neuroprotective prevention and alternate treatment strategies. Anticoagulation does appear to be safe in CSVT and may prevent thrombus progression but clinical equipoise remains, and clinical trials are needed to obtain evidence regarding short- and long-term efficacy outcomes.
No takes yet. Share an insight, caveat, or question.
Sarah H. O’Brien (2015) conducted a review in Perinatal arterial ischemic stroke (PAIS) and cerebral sinovenous thrombosis (CSVT). Perinatal stroke has a multifactorial etiology with limited treatment options; anticoagulation is rarely indicated for arterial ischemic stroke but appears safe for cerebral sinovenous thrombosis.
Synapse has enriched 10 related papers. Consider them for comparative context: